IBDEI0J0 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8552,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,8552,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,8553,0)
 ;;=C82.49^^39^401^77
 ;;^UTILITY(U,$J,358.3,8553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8553,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8553,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,8553,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,8554,0)
 ;;=C82.40^^39^401^78
 ;;^UTILITY(U,$J,358.3,8554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8554,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,8554,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,8554,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,8555,0)
 ;;=C82.99^^39^401^79
 ;;^UTILITY(U,$J,358.3,8555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8555,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8555,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,8555,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,8556,0)
 ;;=C82.90^^39^401^80
 ;;^UTILITY(U,$J,358.3,8556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8556,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,8556,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,8556,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,8557,0)
 ;;=R59.1^^39^401^65
 ;;^UTILITY(U,$J,358.3,8557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8557,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,8557,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,8557,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,8558,0)
 ;;=C91.40^^39^401^84
 ;;^UTILITY(U,$J,358.3,8558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8558,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8558,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,8558,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,8559,0)
 ;;=C91.42^^39^401^82
 ;;^UTILITY(U,$J,358.3,8559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8559,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,8559,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,8559,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,8560,0)
 ;;=C91.41^^39^401^83
 ;;^UTILITY(U,$J,358.3,8560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8560,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,8560,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,8560,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,8561,0)
 ;;=D57.01^^39^401^85
 ;;^UTILITY(U,$J,358.3,8561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8561,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,8561,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,8561,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,8562,0)
 ;;=D57.00^^39^401^86
 ;;^UTILITY(U,$J,358.3,8562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8562,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,8562,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,8562,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,8563,0)
 ;;=D57.02^^39^401^87
 ;;^UTILITY(U,$J,358.3,8563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8563,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,8563,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,8563,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,8564,0)
 ;;=D68.32^^39^401^89
 ;;^UTILITY(U,$J,358.3,8564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8564,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,8564,1,4,0)
 ;;=4^D68.32
